munKNEE.com Your Key to Making Money
I attended an investment presentation last week by a company that is introducing an innovative skin cancer detection device into the Canadian/American markets that was so enlightening, so potentially financially rewarding and so potentially life-saving, that I just have to share it with you. Words: 888
So says Lorimer Wilson, editor of www.munKNEE.com.
Most of us enjoy getting a tan, even if it entails the occasional sunburn but, unfortunately, too much sun can eventually have an adverse affect on your health in the form of skin cancer which is growing at a rate of 10% per year. Indeed, the Canadian and US Cancer societies confirm that skin cancer is the most common form of cancer. Each year there are more new cases of skin cancer than the combined incidence of cancers of the breast, prostrate, lung and colon.
Nearly 800,000 Americans are living with a history of melanoma and 13 million Americans are living with a history of non-melanoma skin cancer, typically diagnosed as basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). When melanoma is detected early, the survival rate is about 99% and falls to 15% as the disease advances.
If you have experienced too many “too much sun” events over the years, however, (or you have some unchecked moles, or have a family history of malignant melanoma,) you may well be making regular visits to your dermatologist to have the unattractive – and potentially deadly – effects of too much sun (lesions, etc.) frozen off with the application of liquid nitrogen (called cryosurgery or cryotherapy) or otherwise treated ( the application of Efudex cream comes to mind). Some of you may have even:
- had an invasive and sometimes painful biopsy of a suspicious looking growth (mole, lesion or some other change in skin appearance),
- had to wait for weeks for the answer as to whether it was benign, skin cancer or malignant melanoma,
- had to schedule and wait for a follow-up appointment and then
- had to schedule, wait and undergo plastic surgery to repair the damage done by the biopsy.
Unfortunately, I know of what I speak as I have been making quarterly visits over the past 20 years to my friendly and accomplished dermatologist undergoing the whole range of treatments.
Well, no more! Future biopsies, and the need to wait for the results (an immediate diagnosis is made during your appointment) will be a thing of the past in large measure (see video here – 4:56 minutes) once family physicians and dermatologists begin practising a new non-invasive skin cancer screening procedure that has been in use in Europe, the UK, Australia for a number of years and has recently been introduced to the medical communities in Canada and the U.S. by MedX Health Corpoation (TSX-V:MDX).
The system is the FDA approved and Health Canada cleared SIMSYS-MoleMate Skin Imaging System ( see a video here – 2:48 minutes – and here – 2:08 minutes) which provides a significant advance in the early detection of potentially life threatening moles and lesions.
MoleMate uses a patented device and technology (MedX has been granted 17 international patents to date and has another 23 patents pending) that features a hand-held scanner designed for office use that utilizes light to view beneath suspicious moles or lesions in a pain free, non-invasive manner, creating images for physicians to evaluate all types of moles and lesions within seconds, providing images that can reveal if a mole is benign, or something more serious, often eliminating the need for skin biopsies, resulting in less pain, scarring, and expense. [See this video – 5:29 minutes – by Dr. Ronald H. Falcon, MD, FAAD on the merits of the SIMSYS-MoleMate.]
It is just a matter of time before this system is owned by every family physician, dermatologist, clinic and hospital in North America so you can just imagine the upcoming growth and increased profits and share price of MedX Health Corp. MedX is a 12 year old Canadian company, headquartered in Mississauga, Ontario (Toronto). MDX trades on the TSX Venture Exchange under the symbol TSXV:MDX and currently trades in the $0.09 range.
Physicians have found that the SIMSYS-MoleMate Siascope hand-held device:
- is easy to learn how to use via the 60-90 minute training CD,
- rapidly provides accurate images of the pigment, blood, and collagen below the mole or lesion,
- provides clear precise PDF reports for patient records and referrals,
- allows patient interaction and improved education and
- raises the profile and enhances the service offering of a practice.
Thankfully, physicians in Canada and the U.S. can now more accurately evaluate suspicious moles and lesions in a non-invasive, pain-free way as a result of the introduction of MedX’s MoleMate detection system and, in the course of reducing the need for time-consuming and expensive biopsies, save the health care systems and/or patients major expense.
Having read this article please consider forwarding it to your family physician and dermatologist and speaking to your financial advisor about buying some shares in MedX Health Corp. It could be an investment in your future good health and your future financial well-being.
To see the actual medX presentation go here.
For more information about SIMSYS-MoleMate (TSXV: MDX) contact:
MedX Health Corp.; (905) 670-4428 or (888) 368-3112
info@medxhealth.com; www.simsys-molemate.com